Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS

Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.

Related Keywords

New York ,United States ,Sunil Iyer ,Oncologic Drugs Advisory Committee ,Meeting Of The Oncologic Drugs Advisory Committee ,Columbia University Irving Medical Center ,International Prognostic Scoring System ,Drugs Advisory Committee ,Science Summit ,New York City ,D ,Mds ,Lower Risk Myelodysplastic Syndrome ,Imetelstat ,Phase 2 3 Imerge Mds3001 Trial Nct02598661 ,